-
Mashup Score: 7
Ivy Riano: Tips to advise on how to plan your ASCO annual meeting / ASCO, ASCO Annual Meeting, cancer, Dartmouth-Hitchcock, early career oncologists, Ivy
Source: oncodaily.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 7
Ivy Riano: Tips to advise on how to plan your ASCO annual meeting / ASCO, ASCO Annual Meeting, cancer, Dartmouth-Hitchcock, early career oncologists, Ivy
Source: oncodaily.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 5Don't miss out on an engaging Tweetorial by Florez Lab and Young Lung Cancer Initiative - OncoDaily - 13 day(s) ago
Don’t miss out on an engaging Tweetorial by Florez Lab and Young Lung Cancer Initiative / cancer, Florez Lab, Lung cancer, OncoDaily, Oncology, tweetorial,
Source: oncodaily.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2Toni Choueiri: The February ASCO Plenary Series are here - OncoDaily - 4 month(s) ago
Toni Choueiri: The February ASCO Plenary Series are here / ASCO, ASCO Plenary Series, cancer, DREAMM-7, FRUTIGA, gastric/GE junction adenocarcinoma,
Source: oncodaily.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 9The Influence of Obesity on Outcomes with Immune Checkpoint Blockade: Clinical Evidence and Potential Biological Mechanisms - 6 month(s) ago
Immune checkpoint blockade (ICB) is a mainstay of treatment for advanced cancer, yet tumor response and host toxicity are heterogenous in those patients who receive ICB. There is growing interest in understanding how host factors interact with tumor intrinsic properties and the tumor microenvironment to influence the therapeutic index with ICB. Obesity, defined by body mass index, is a host factor associated with improved outcomes in select cancers when treated with ICB. While the biological mechanism for this obesity paradox is not fully understood, pre-clinical and translational studies suggest obesity may potentially impact tumor metabolism, inflammation, and angiogenesis. Herein, we summarize clinical studies that support an obesity paradox with ICB, explore potential biological mechanisms that may account for the obesity paradox, and address methodological challenges to consider when studying obesity and treatment outcomes.
Source: www.mdpi.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 8The Influence of Obesity on Outcomes with Immune Checkpoint Blockade: Clinical Evidence and Potential Biological Mechanisms - 6 month(s) ago
Immune checkpoint blockade (ICB) is a mainstay of treatment for advanced cancer, yet tumor response and host toxicity are heterogenous in those patients who receive ICB. There is growing interest in understanding how host factors interact with tumor intrinsic properties and the tumor microenvironment to influence the therapeutic index with ICB. Obesity, defined by body mass index, is a host factor associated with improved outcomes in select cancers when treated with ICB. While the biological mechanism for this obesity paradox is not fully understood, pre-clinical and translational studies suggest obesity may potentially impact tumor metabolism, inflammation, and angiogenesis. Herein, we summarize clinical studies that support an obesity paradox with ICB, explore potential biological mechanisms that may account for the obesity paradox, and address methodological challenges to consider when studying obesity and treatment outcomes.
Source: www.mdpi.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 8The Influence of Obesity on Outcomes with Immune Checkpoint Blockade: Clinical Evidence and Potential Biological Mechanisms - 6 month(s) ago
Immune checkpoint blockade (ICB) is a mainstay of treatment for advanced cancer, yet tumor response and host toxicity are heterogenous in those patients who receive ICB. There is growing interest in understanding how host factors interact with tumor intrinsic properties and the tumor microenvironment to influence the therapeutic index with ICB. Obesity, defined by body mass index, is a host factor associated with improved outcomes in select cancers when treated with ICB. While the biological mechanism for this obesity paradox is not fully understood, pre-clinical and translational studies suggest obesity may potentially impact tumor metabolism, inflammation, and angiogenesis. Herein, we summarize clinical studies that support an obesity paradox with ICB, explore potential biological mechanisms that may account for the obesity paradox, and address methodological challenges to consider when studying obesity and treatment outcomes.
Source: www.mdpi.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 8The Influence of Obesity on Outcomes with Immune Checkpoint Blockade: Clinical Evidence and Potential Biological Mechanisms - 6 month(s) ago
Immune checkpoint blockade (ICB) is a mainstay of treatment for advanced cancer, yet tumor response and host toxicity are heterogenous in those patients who receive ICB. There is growing interest in understanding how host factors interact with tumor intrinsic properties and the tumor microenvironment to influence the therapeutic index with ICB. Obesity, defined by body mass index, is a host factor associated with improved outcomes in select cancers when treated with ICB. While the biological mechanism for this obesity paradox is not fully understood, pre-clinical and translational studies suggest obesity may potentially impact tumor metabolism, inflammation, and angiogenesis. Herein, we summarize clinical studies that support an obesity paradox with ICB, explore potential biological mechanisms that may account for the obesity paradox, and address methodological challenges to consider when studying obesity and treatment outcomes.
Source: www.mdpi.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1How I Became a Hematology/Oncology Fellow, Cancer Researcher, and - 9 month(s) ago
Dr. Nazli Dizman has traveled across the world to pursue her passion for clinical and translational cancer research and further her career as a medical oncologist.
Source: connection.asco.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 4KCRS | The Kidney Cancer Research Summit by KidneyCAN - 10 month(s) ago
KCRS is the annual Kidney Cancer Research Summit presented by KidneyCAN. KCRS is a meeting focused on basic and translational science, as well as cutting edge translational research. The research presented at KCRS is fueled by the funding from the Department of Defense CDMRP – KCRP awards.
Source: kcrs.kidneycan.orgCategories: Hem/Oncs, Latest HeadlinesTweet
RT @oncodaily: Tips to advise on how to plan your @ASCO annual meeting - @IvyLorena_Md @CamilaBragancaX https://t.co/moIazl1xJs #ASCO #…